---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004634"
form_type: "8-K"
ticker: "PLSH"
cik: "0001552189"
company_name: "PANACEA LIFE SCIENCES HOLDINGS, INC."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:45:08.916760+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Panacea Life Sciences agrees to repay $385K convertible note via cash and equity conversion

## Summary
- Company to pay $135,000 funded under CEO line of credit on Feb 13, 2023; $100,000 by June 30, 2023.
- Conversion of 540,000 common shares at fixed price of $0.25 per share to satisfy remaining balance.
- Note Payoff Agreement dated Feb 9, 2023 amends prior Share Exchange Agreement from March 2022.

## SEC filing metadata
- accession: 0001493152-23-004634
- form_type: 8-K
- ticker: PLSH
- cik: 0001552189
- company_name: PANACEA LIFE SCIENCES HOLDINGS, INC.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552189/000149315223004634/0001493152-23-004634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552189/000149315223004634/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004634
- JSON: https://secwatch.observer/filing/0001493152-23-004634.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004634.txt

## Key facts
- Material Agreements
  PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Exchange of 350 shares of Series A Preferred Stock for Senior Convertible Note of $385,000, subseque (effective 2022-03-03).
  - Action: entry
  - Counterparty: institutional investor
  - Value: Exchange of 350 shares of Series A Preferred Stock for Senior Convertible Note of $385,000, subseque
  - Effective: 2022-03-03
  source text: On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1552189/000149315223004634/0001493152-23-004634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.